AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions

Accessing IMS Health’s European electronic health records and jointly building a customized data analysis platform will inform AstraZeneca’s R&D priorities and support outcomes claims of newly-launched drugs.

More from Europe

More from Geography